1.51
前日終値:
$1.58
開ける:
$1.5
24時間の取引高:
1.26M
Relative Volume:
0.40
時価総額:
$85.56M
収益:
-
当期純損益:
$-82.44M
株価収益率:
-0.8032
EPS:
-1.88
ネットキャッシュフロー:
$-66.75M
1週間 パフォーマンス:
-9.58%
1か月 パフォーマンス:
-20.94%
6か月 パフォーマンス:
-58.74%
1年 パフォーマンス:
-69.80%
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
名前
Black Diamond Therapeutics Inc
セクター
電話
617-417-5868
住所
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
BDTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BDTX
Black Diamond Therapeutics Inc
|
1.51 | 85.56M | 0 | -82.44M | -66.75M | -1.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-31 | 開始されました | Raymond James | Outperform |
2023-07-14 | 開始されました | Piper Sandler | Overweight |
2023-06-30 | アップグレード | Stifel | Hold → Buy |
2023-06-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
2023-06-27 | アップグレード | Wedbush | Neutral → Outperform |
2022-03-29 | ダウングレード | Wedbush | Outperform → Neutral |
2022-03-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2021-09-30 | 開始されました | Stifel | Hold |
2021-01-07 | 開始されました | Wedbush | Outperform |
2020-11-24 | 開始されました | Berenberg | Buy |
2020-05-04 | 開始されました | H.C. Wainwright | Buy |
2020-02-24 | 開始されました | Canaccord Genuity | Buy |
2020-02-24 | 開始されました | Cowen | Outperform |
2020-02-24 | 開始されました | JP Morgan | Overweight |
2020-02-24 | 開始されました | Jefferies | Buy |
すべてを表示
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Small Cap Stocks To Follow TodayMarch 19th - MarketBeat
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com India
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Black Diamond Therapeutics Reports 2024 Financial Results - MSN
Black Diamond Therapeutics: In Decline, But Why? (NASDAQ:BDTX) - Seeking Alpha
Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $1.76 amid market challenges - Investing.com Australia
BDTX stock touches 52-week low at $1.76 amid market challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Brokers Issue Forecasts for BDTX Q1 Earnings - Defense World
Stifel Nicolaus Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00 - Defense World
Wedbush Reiterates Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):